Acalabrutinib

Chemical formula: C₂₆H₂₃N₇O₂  Molecular mass: 465.517 g/mol  PubChem compound: 71226662

Therapeutic indications

Acalabrutinib is indicated for:

Mantle cell lymphoma - monotherapy

Population group: only adults (18 years old or older)

Acalabrutinib as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) not previously treated with a BTK inhibitor.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Chronic lymphocytic leukaemia in previously treated patients - monotherapy

Population group: only adults (18 years old or older)

Acalabrutinib as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Small lymphocytic lymphoma

Population group: only adults (18 years old or older)

Acalabrutinib is indicated for the treatment of adult patients with small lymphocytic lymphoma (SLL).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Acalabrutinib is contraindicated in the following cases:

Lactation

Lactation

Strong CYP3A/P-gp inhibitors

at least one of
Strong CYP3A4 inhibitors
Cytochrome P-450 CYP3A5 strong inhibitors
and additionally P-glycoprotein inhibitors

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2025: CALQUENCE Hard capsule
Structured Product Labeling (SPL/PLR) 2019: CALQUENCE Capsule
Summary of Product Characteristics (SPC) 2025: CALQUENCE Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈